open access

Vol 11, No 3 (2007)
Prace oryginalne
Published online: 2007-05-31
Get Citation

Influence of PPARγ agonists and polymorphism Pro12 Ala on blood pressure values in patients with type 2 diabetes. Initial coverage

Małgorzata Gacka, Tadeusz Dobosz, Stanisław Szymaniec, Dorota Bednarska-Chabowska, Arleta Lebioda, Rajmund Adamiec
Nadciśnienie tętnicze 2007;11(3):215-222.

open access

Vol 11, No 3 (2007)
Prace oryginalne
Published online: 2007-05-31

Abstract


Background PPARγ is a transcriptor factor with wide spectrum activity. Its expression disorders, connected with polymorphic variants, are responsible for obesity, insulin resitance and also hypertension. The aim of this study was to assess the influence of PPARγ agonist (roziglitazon) and polymorphism Pro12Ala of this receptor on blood pressure values in type 2 diabetes
Material and methods In 45 patients, who were treated sulfonylurea and metformin with inadequate metabolic control and insulin resitance, rosiglitazone 4 mg per day was administered. Polymorphism Pro12Ala was estimated [SnaPshot; ABI PRISM310]. In 45 patients with type 2 diabetes before and following 22 weeks of rosiglitazone therapy blood pressure valuses were estimated (mean of three measurments). Other tests were conducted using routine lab tests.
Results A heterozygous genotyp Pro12Ala was found in 12 patients and and a homozygous genotyp Pro12Pro in 33 patients. Following rosiglitazone therapy a statistically significant downward tendency of systolic blood pressure valuses was noted (before: 145.35 ± 20.25 mm Hg vs. after: 139.40 ± 15.39 mm Hg; p < 0.045 ). A downward tendency of diastolic blood pressure valuses was observed as well, but it did not achieve significance level (before: 86.37 ± 10.77 vs. after: 83.73 ± 10.19 [mm Hg]; p = 0.170). Blood pressure reduction was noted only in patients with genotype Pro12Ala PPARγ (p < 0.023). A statistically significant downward tendency of blood pressure was not noted in patients with Pro12Pro genotype (p = 0.307).
Conclusions 1. Exogenous stimulation of PPARγ receptor is connected with statistically significant downward tendency of systolic blood pressure values. 2. Hypotensive effect of rosiglitazone appears first in all patients with Pro12Ala genotype.

Abstract


Background PPARγ is a transcriptor factor with wide spectrum activity. Its expression disorders, connected with polymorphic variants, are responsible for obesity, insulin resitance and also hypertension. The aim of this study was to assess the influence of PPARγ agonist (roziglitazon) and polymorphism Pro12Ala of this receptor on blood pressure values in type 2 diabetes
Material and methods In 45 patients, who were treated sulfonylurea and metformin with inadequate metabolic control and insulin resitance, rosiglitazone 4 mg per day was administered. Polymorphism Pro12Ala was estimated [SnaPshot; ABI PRISM310]. In 45 patients with type 2 diabetes before and following 22 weeks of rosiglitazone therapy blood pressure valuses were estimated (mean of three measurments). Other tests were conducted using routine lab tests.
Results A heterozygous genotyp Pro12Ala was found in 12 patients and and a homozygous genotyp Pro12Pro in 33 patients. Following rosiglitazone therapy a statistically significant downward tendency of systolic blood pressure valuses was noted (before: 145.35 ± 20.25 mm Hg vs. after: 139.40 ± 15.39 mm Hg; p < 0.045 ). A downward tendency of diastolic blood pressure valuses was observed as well, but it did not achieve significance level (before: 86.37 ± 10.77 vs. after: 83.73 ± 10.19 [mm Hg]; p = 0.170). Blood pressure reduction was noted only in patients with genotype Pro12Ala PPARγ (p < 0.023). A statistically significant downward tendency of blood pressure was not noted in patients with Pro12Pro genotype (p = 0.307).
Conclusions 1. Exogenous stimulation of PPARγ receptor is connected with statistically significant downward tendency of systolic blood pressure values. 2. Hypotensive effect of rosiglitazone appears first in all patients with Pro12Ala genotype.
Get Citation

Keywords

Pro12Ala polymorphism; PPARγ; hypertension; type 2 diabetes; rosiglitazone

About this article
Title

Influence of PPARγ agonists and polymorphism Pro12 Ala on blood pressure values in patients with type 2 diabetes. Initial coverage

Journal

Arterial Hypertension

Issue

Vol 11, No 3 (2007)

Pages

215-222

Published online

2007-05-31

Bibliographic record

Nadciśnienie tętnicze 2007;11(3):215-222.

Keywords

Pro12Ala polymorphism
PPARγ
hypertension
type 2 diabetes
rosiglitazone

Authors

Małgorzata Gacka
Tadeusz Dobosz
Stanisław Szymaniec
Dorota Bednarska-Chabowska
Arleta Lebioda
Rajmund Adamiec

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl